“Efficacy and Safety of IL-5 Pathway-Targeting Biologics (Mepolizumab, Reslizumab, Benralizumab) in the Management of Hypereosinophilic Syndromes: A Systematic Review and Meta-Analysis” (2025) Open Access Indonesian Journal of Medical Reviews, 5(5), pp. 607–626. doi:10.37275/oaijmr.v5i5.780.